Kelly Ann D. Pryor
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Peptidase Inhibition and Analysis, Neuropeptides and Animal Physiology, Bacterial Genetics and Biotechnology, Neuroendocrine Tumor Research Advances
Most-Cited Works
- → Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes(2005)490 cited
- → Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1(2010)176 cited
- → A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice(2017)88 cited
- → Crystallization and preliminary X-ray analysis of the Escherichia coli UDP-MurNAc-tripeptide D-alanyl-D-alanine-adding enzyme (MurF)(1999)9 cited